Genetex
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 1997 |
| Founder | Joel B. Baseman, C. Kent Osborne, Wen-Hwa Lee, Eva Y.-H. P. Lee |
| Headquarters | Irvine, California , United States |
Area served | Global |
| Products | Research antibodies, recombinant proteins, life science reagents |
| Website | www |
GeneTex, Inc. operates as a global biotechnology enterprise focused on life science reagents, specializing in the creation, licensing, and distribution of research antibodies alongside associated products. Its extensive inventory comprises close to 50,000 items, including antibodies, recombinant proteins, and various reagents designed for both academic and industrial scientists working in fundamental and translational biomedical research. GeneTex’s product range spans multiple disciplines such as cancer biology, neuroscience, cell biology, infectious diseases, metabolism, epigenetics, immunology, among others. The firm utilizes a recombinant monoclonal antibody production system combined with sophisticated validation methodologies to guarantee uniform quality, scalability, and dependability.
History
Established in 1997 in San Antonio, Texas by researchers Joel B. Baseman, C. Kent Osborne, Wen-Hwa Lee, and Eva Y.-H. P. Lee, GeneTex broadened its operations in 2007 by inaugurating manufacturing and R&D sites in Taiwan. The company moved its U.S. headquarters to Irvine, California in 2009 to be closer to leading universities and biotechnology clusters. In 2020, GeneTex made additional investments in Taiwan by launching new facilities dedicated to recombinant monoclonal antibody manufacturing and strengthened quality control measures.
Recombinant monoclonal antibody technology
GeneTex incorporated recombinant monoclonal antibody technology into its development platform in 2020 to supplement its existing polyclonal and hybridoma monoclonal antibody offerings. This strategic transition responded to industry movements favoring renewable antibody sources and fulfilled researchers’ evolving needs. Since adopting this method, the majority of new antibody generation has utilized this technology due to its benefits in reproducibility and production scalability. The technique involves fluorescence-activated cell sorting (FACS) to isolate antigen-specific memory B cells from immunized specimens. Subsequently, the variable regions of heavy and light chains are cloned into an immunoglobulin G (IgG) framework and expressed within mammalian cell cultures. This efficient process enables development completion within weeks while minimizing animal usage through scalable bioreactor systems.
Product Quality and Validation
Commitment to consistency and reliability is maintained by GeneTex through compliance with ISO 9001:2015, ISO 13485:2016, and ISO 14001:2015 certifications. The company performs thorough validation of its antibodies for applications including western blotting (WB), immunoprecipitation (IP), immunohistochemistry (IHC), immunocytochemistry (ICC/IF), flow cytometry (FCM), and ELISA assays. Its antibody characterization protocol follows a comprehensive “Five-Pillar Validation” approach encompassing: (1) Knockout/Knockdown testing, (2) Comparison with similar antibodies, (3) Immunoprecipitation combined with mass spectrometry (IP/MS), (4) Biological function assessment and orthogonal validation techniques, and (5) Expression analysis using recombinant proteins.